U.S. Life Sciences Stock News

UFP Technologies (NasdaqCM:UFPT) amended its manufacturing supply agreement with Intuitive Surgical. The amendment extends the term of the partnership between the two companies. Minimum volume commitments under the agreement were increased. A new program for additional products was added to the supply arrangement. For you as an investor, this centers on UFP Technologies' role as a specialized manufacturer for the medical device sector, supplying components and solutions to a leading global...

Exzeo Group has entered into a new partnership with Tokio Marine Highland to distribute TMH2O residential flood insurance. The collaboration expands Exzeo’s property insurance offerings and supports its ambitions as a multi-line, technology driven platform. For investors tracking NYSE:XZO, this announcement comes as the stock trades at $16.1, with a 3.7% gain over the past week and a 20.8% decline over the past month. Year to date, shares show a 29.3% decline, so this move may stand out as...

U.S. Gold Corp. recently presented at the Emerging Growth Virtual Conference on February 25, 2026, with Executive Chairman Luke Anthony Norman addressing investors. This appearance gave the company a platform to highlight its latest corporate developments and project plans directly to a broad investment audience. We’ll now explore how U.S. Gold Corp.’s Emerging Growth Virtual Conference presentation could shape its investment narrative and investor expectations. The best AI stocks today may...

Why Sabre stock is drawing fresh attention after its latest earnings Sabre (SABR) has moved back into the spotlight after reporting fourth quarter and full year 2025 results that shifted the company from a net loss to positive net income for the year. For investors tracking travel technology names, that change in profitability and earnings per share, alongside ongoing quarterly losses, raises fresh questions about how to weigh Sabre’s recent performance against its longer term return...

Empire State Realty OP (ESBA) just wrapped up FY 2025 with Q4 total revenue of US$199.7 million and basic EPS of US$0.13, while trailing twelve month revenue sits at US$768.3 million and EPS at US$0.27. Over the past few quarters, revenue has moved from US$197.6 million in Q4 2024 to US$199.7 million in Q4 2025, with quarterly EPS shifting from US$0.07 to US$0.13. This sets up a picture where investors will be weighing these earnings against a 9.5% net margin and the impact of a one off gain...

Tegna (TGNA) has laid out its FY 2025 scorecard so far with Q3 revenue of US$650.8 million and basic EPS of US$0.23, alongside trailing twelve month revenue of about US$2.9 billion and EPS of US$2.13 that sit against a net profit margin of 11.9%. The company has seen quarterly revenue move from US$710.4 million in Q2 2024 to US$675.0 million in Q2 2025, with EPS shifting from US$0.48 to US$0.42 over the same period, as trailing earnings also reflect a one off US$139.1 million gain that shapes...

Farmers National Banc recently drew heightened attention as a regional lender with a traditional community banking model centered on Ohio and nearby Midwest markets, where it is contending with margin pressure from higher deposit costs and slower loan repricing. What makes this situation especially important is the combination of rising credit risks in commercial real estate and small business portfolios with questions about how regulatory scrutiny and the interest‑rate backdrop could affect...

Why Empire State Realty Trust is back on investors’ radar Empire State Realty Trust (ESRT) has moved back into focus after fourth quarter 2025 results showed higher quarterly revenue and net income year over year, alongside fresh leasing wins with major tenants. For the fourth quarter, ESRT reported sales of US$159.72 million and revenue of US$199.22 million, compared with US$155.13 million and US$197.6 million a year earlier. Net income came in at US$20.73 million versus US$12.22 million,...

Fulgent Genetics (FLGT) is back on investors’ radar after its latest update, with 2025 earnings showing US$322.67 million in sales, a wider net loss, and fresh 2026 revenue guidance of about US$350 million. See our latest analysis for Fulgent Genetics. The share price reaction has been sharp, with a 1 day share price return of a 38.09% decline and a year to date share price return of a 40.09% decline, even though the 1 year total shareholder return is roughly flat. This suggests recent...

Anywhere Real Estate Inc. has released its full-year 2025 results, reporting revenue of US$5,960 million compared with US$5,692 million in 2024, and a net loss of US$90 million versus US$128 million previously. The combination of higher revenue and a smaller net loss points to operational progress that investors may see as a sign of improving financial health, even though the business remains loss-making. We’ll now examine how this revenue growth and reduced net loss might reshape Anywhere...

If you are wondering whether Day One Biopharmaceuticals' current share price lines up with its underlying worth, you are not alone. The stock most recently closed at US$10.60, with a 7 day return of 10% decline, a 30 day return of 5% decline, gains of 19.8% year to date and 17% over the past year, while the 3 year return sits at 43.4% decline. Recent news around Day One has largely focused on its development stage oncology pipeline and ongoing progress in clinical programs, which can...

Perimeter Solutions (NYSE:PRM) is dealing with operational and safety issues at its Sauget P2S5 facility that have led to reduced production and ongoing litigation as it seeks to take control of the site. The company has recently closed a sizeable acquisition while shifting more of its portfolio toward fixed and recurring contracts to support more consistent earnings. These developments affect a key production asset and the structure of Perimeter Solutions' revenue, with potential...

Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo. The company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies. Pivotal clinical trials are in progress that could support label expansions and additional indications. Syndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...

Flywire appointed Patrick Blanc as Chief Technology Officer as part of a leadership realignment focused on AI driven product development. Blanc brings payments technology experience from senior roles at Ingenico, Visa, and PayPal. David King moved into the role of Chief Product Officer and Co President of Global Education to support Flywire's product and sector focus. For investors tracking NasdaqGS:FLYW, this leadership reshuffle comes with the stock recently closing at $12.31 and showing...

If you are wondering whether LegalZoom.com’s current share price reflects its true worth, you are not alone. This article focuses on what the numbers say about value. The stock last closed at US$7.03, with a 7 day return of 7.2%, but declines of 20.9% over 30 days, 26.7% year to date, and 30.8% over the past year. These moves have put valuation questions front and center for many investors, who are weighing short term swings against the longer term picture. Evergreen coverage like this aims...

Daktronics (NasdaqGS:DAKT) has agreed to supply an integrated digital display system across the OCVIBE campus, a large mixed-use development project. The company also announced an executive leadership change, with the former Interim President and CEO moving into an advisory role. Both updates relate to Daktronics' positioning in large commercial installations and its ongoing leadership structure. Daktronics focuses on electronic scoreboards, digital signage, and large-format LED video...

Ginkgo Bioworks Holdings (DNA) is back in focus after reporting 2025 results that combined smaller losses and lower cash burn with a clear pivot toward robotics-powered autonomous labs and a planned biosecurity divestiture. See our latest analysis for Ginkgo Bioworks Holdings. The earnings release, biosecurity divestiture plan, and new autonomous lab contracts have coincided with heavy selling, including a 30.48% 1-day share price return decline and a 26.79% 7-day share price return decline...

Herc Holdings (NYSE:HRI) has completed its largest acquisition to date, expanding its equipment rental footprint across local markets. The company is now concentrating on post-merger integration, including combining operations, systems, and teams across the enlarged network. Management is prioritizing cost synergies, higher used equipment sales, and branch network changes following the closing of the deal. Herc Holdings runs a broad equipment rental business that serves construction,...

In late February 2026, Thryv Holdings filed an US$8.15 million shelf registration for 2,179,185 common shares tied to its ESOP and reported fourth-quarter 2025 results showing quarterly sales of US$191.62 million, a net loss of US$9.66 million, and full-year 2025 sales of US$785.02 million with net income of US$0.31 million. Beyond the headline figures, the results underscored Thryv’s rapid pivot toward higher-margin SaaS and AI-powered tools, with SaaS revenue rising sharply, margins...

GoodRx Holdings recently reported fourth-quarter 2025 results, issued 2026 revenue guidance of US$750 million to US$780 million, updated progress on its share buyback, filed a US$74.72 million shelf registration for an ESOP-related Class A stock offering, and disclosed several analyst rating changes. The company also launched GoodRx Employer Direct, a new program that lets employers directly subsidize high-cost drugs like GLP-1s at the pharmacy counter, potentially widening GoodRx’s role in...

Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year. See our latest analysis for Xponential Fitness. The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of...

Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030. While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and...

If you are trying to work out whether Lineage at around US$40.52 is a bargain or just fairly priced, you are in the right place. The stock has recently posted returns of 5.8% over 7 days, 12.6% over 30 days and 14.4% year to date, although the 1 year return sits at a 29.3% decline. Recent attention on Lineage has focused on its position in the US real estate space and how investors are reassessing companies in the sector, which helps frame these recent price moves. Coverage has regularly...

Why Aspen Aerogels is back in focus Aspen Aerogels (ASPN) is back on investors’ radar after reporting a sharp year over year revenue decline, a large full year net loss, a sizeable impairment charge, and guidance indicating continued losses. See our latest analysis for Aspen Aerogels. The stock’s recent swings reflect this reset in expectations, with a 7 day share price return showing a 13.57% decline and a 1 year total shareholder return indicating a 59% loss, highlighting how pressure has...